Kristien Sleurs1, Sven F Seys2,3, Jean Bousquet4, Wytske J Fokkens5, Senne Gorris1, Benoit Pugin2,3, Peter W Hellings1,2,5. 1. Department of Otorhinolaryngology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. 2. Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium. 3. EUFOREA, European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium. 4. Department of Respiratory Disease, University Hospital Arnaud de Villeneuve, Montpellier, France. 5. Department of Otorhinolaryngology, Academic Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND: The market of mobile health (mHealth) technology is rapidly evolving, making new mobile technologies potentially available for healthcare systems. Patient empowerment through self-monitoring of symptoms, shared decision making with the physician, and easily accessible education are important features extending the reach of mHealth technology beyond traditional care. METHODS: Two digital distribution platforms (Apple App Store and Google Play Store) were searched for currently available mobile applications (apps) for patients with chronic respiratory diseases (CRDs). A new index (score ranging from 0 to 10) was developed to assess the potential of apps as a tool to empower patients through mobile technology (based on self-monitoring, personalized feedback, and patient education app features). RESULTS: One hundred and twelve apps were retained for analysis and could be classified in 5 categories: Asthma (n = 71), COPD (n = 15), Asthma and COPD (n = 15), Rhinitis and Asthma (n = 5), and Rhinosinusitis (n = 6). Eighty percent were developed by medical technology companies compared to 18% by medical doctors and 2% by pharmaceutical companies. Two-thirds of apps allow disease self-monitoring, whereas over half of apps provide patient feedback through graphs. Sixty percent of apps contain easily accessible patient education material. Only three percent of apps reach a score of ≥7 on the newly designed patient empowerment index. CONCLUSIONS: A variety of apps are available for patients with CRDs of which only few were developed by or jointly with medical doctors. The majority of these apps include self-monitoring tools, but only few also provide personalized feedback, which is needed to adopt these apps into daily care.
BACKGROUND: The market of mobile health (mHealth) technology is rapidly evolving, making new mobile technologies potentially available for healthcare systems. Patient empowerment through self-monitoring of symptoms, shared decision making with the physician, and easily accessible education are important features extending the reach of mHealth technology beyond traditional care. METHODS: Two digital distribution platforms (Apple App Store and Google Play Store) were searched for currently available mobile applications (apps) for patients with chronic respiratory diseases (CRDs). A new index (score ranging from 0 to 10) was developed to assess the potential of apps as a tool to empower patients through mobile technology (based on self-monitoring, personalized feedback, and patient education app features). RESULTS: One hundred and twelve apps were retained for analysis and could be classified in 5 categories: Asthma (n = 71), COPD (n = 15), Asthma and COPD (n = 15), Rhinitis and Asthma (n = 5), and Rhinosinusitis (n = 6). Eighty percent were developed by medical technology companies compared to 18% by medical doctors and 2% by pharmaceutical companies. Two-thirds of apps allow disease self-monitoring, whereas over half of apps provide patient feedback through graphs. Sixty percent of apps contain easily accessible patient education material. Only three percent of apps reach a score of ≥7 on the newly designed patient empowerment index. CONCLUSIONS: A variety of apps are available for patients with CRDs of which only few were developed by or jointly with medical doctors. The majority of these apps include self-monitoring tools, but only few also provide personalized feedback, which is needed to adopt these apps into daily care.
Authors: Ayşe Arzu Yorgancıoğlu; Bilun Gemicioğlu; Cemal Cingi; Ömer Kalaycı; Ali Fuat Kalyoncu; Claus Bachert; Peter Hellings; Oliver Pfaar; Holger J Schünemann; Dana Wallace; Anna Bedbrook; Wienczyslawa Czarlewski; Jean Bousquet Journal: Turk Thorac J Date: 2020-03-01
Authors: Mina Gaga; Pippa Powell; Marta Almagro; Ioanna Tsiligianni; Stelios Loukides; Josep Roca; Matthew Cullen; Anita K Simonds; Brian Ward; Isabel Saraiva; Thierry Troosters; Carlos Robalo Cordeiro Journal: ERJ Open Res Date: 2019-09-25
Authors: Sven F Seys; Shana De Bont; Wytske J Fokkens; Claus Bachert; Isam Alobid; Manuel Bernal-Sprekelsen; Leif Bjermer; Ina Callebaut; Lars-Olaf Cardell; Sean Carrie; Paolo Castelnuovo; Russell Cathcart; Jannis Constantinidis; Leen Cools; Marjolein Cornet; Gregory Clement; Tony Cox; Lieve Delsupehe; Jaime Correia-de-Sousa; Lauren Deneyer; Geert De Vos; Zuzana Diamant; Maria Doulaptsi; Simon Gane; Philippe Gevaert; Claire Hopkins; Valérie Hox; Thomas Hummel; Werner Hosemann; Raf Jacobs; Mark Jorissen; Anette Kjeldsen; Basile N Landis; Winde Lemmens; Andreas Leunig; Valerie Lund; Gert Mariën; Joaquim Mullol; Metin Onerci; Susanna Palkonen; Isabel Proano; Emmanuel Prokopakis; Dermot Ryan; Herbert Riechelmann; Pernilla Sahlstrand-Johnson; Sanna Salmi-Toppila; Christine Segboer; Kato Speleman; Andreas Steinsvik; Pavol Surda; Peter-Valentin Tomazic; Olivier Vanderveken; Laura Van Gerven; Thibaut Van Zele; Jan Verfaillie; Benedicte Verhaeghe; Kathie Vierstraete; Stephan Vlaminck; Martin Wagenmann; Benoit Pugin; Peter W Hellings Journal: Allergy Date: 2020-06-19 Impact factor: 13.146
Authors: Sonia Herrero Martín; Javier Hueto Pérez de Heredia; Alberto Cuesta Remón; Marisol Gómez Fernández; María M Antón; Juan Cabasés; Ruth García Rey; Pilar Cebollero Rivas Journal: Arch Bronconeumol Date: 2021-06-16 Impact factor: 6.333
Authors: Stephanie Dramburg; María Marchante Fernández; Ekaterina Potapova; Paolo Maria Matricardi Journal: Front Immunol Date: 2020-09-10 Impact factor: 7.561